An orphan drug firm has submitted a petition asking FDA's drug center to stop requiring user fee payments while a waiver request is pending. The firm charges that the agency's current policy of requiring firms to pay user-fees before FDA decides if a waiver should be granted is unlawful. The company also asks the agency to transfer responsibility for the user-fee program from the drug center back to the commissioner's office.